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Abstract
Aim To assess whether preoperative statin therapy is associ-
ated with the risk of postoperative infection in patients under-
going cardiac surgery.
Methods 520 patients undergoing cardiac surgery in 2010
were retrospectively examined. Data regarding statin and an-
tibiotic use prior to and after surgery were available from the
hospital pharmacy information system. Cultures and clinical
data of patients on postoperative antibiotics other than stan-
dard prophylactic therapy were studied to identify postopera-
tive infections up to 30 days from day of surgery.
Results 370 (71.2 %) patients were on preoperative statin
therapy. Overall, 82 patients (15.8 %) suffered from postop-
erative infection of which 11 were surgical site infections. In
multivariable regression analysis, statin therapy was associated
with a reduced risk of postoperative infection (adjusted odds
ratio: 0.329, 95 %: CI 0.19–0.57; P<0.001).
Conclusions Preoperative statin use was associated with a
considerable reduced risk of postoperative infections following
cardiac surgery. Randomised controlled trials are required to
clarify the role of statin therapy in the prevention of postoper-
ative infections.
Keywords Statins . Postoperative infection . Cardiac
surgery . Surgical site infection
Introduction
Annually, approximately 16,000 patients are scheduled for
cardiothoracic surgery in the Netherlands. [1] Postoperative
infections are important causes of increased length of hospital
stay and mortality. Despite prophylactic antibiotic therapy, the
incidence of postoperative infectious complications is 5 to
21 % [2–4].
In a search for additional ways to decrease the postopera-
tive infection rate, statin therapy is gaining increasing atten-
tion. In addition to cholesterol-lowering characteristics, statins
have anti-inflammatory, immunomodulatory, antioxidant and
antiapoptotic effects that could alter the response to infections.
[5] Whether statins have a beneficial effect on postoperative
infectious complications in patients undergoing cardiac sur-
gery is unknown, as prior studies have shown conflicting
results [6–8].
This study aims to assess whether preoperative statin therapy
is associated with the risk of postoperative infection in patients
undergoing cardiac surgery.
Methods
Study population
The total population of 1868 adult patients who had undergone
cardiac surgery in the St. Antonius Hospital, Nieuwegein, the
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Netherlands in 2010 was the target population for this study.
From this population we selected all patients with data on
preoperative drug use in the hospital pharmacy information
system. This means that only patients who were hospitalised
more than 24 h before the day of surgery could be studied
(n=593), as these are the patients with reviewed preopera-
tive medication profiles available in the hospital pharmacy
information system. Additionally, 73 patients were excluded
as they were on antimicrobial therapy prior to their surgical
procedure outside the routine antimicrobial prophylaxis
(cefazolin 2 g intravenously before skin incision followed
by additional cefazolin every four hours for the duration of
the procedure and continued up to 48 h for patients with
valve or aortic surgery with exogenous materials). Finally,
all patients with a statin in the preoperative medication
profile were considered exposed at the time of surgery
and all other patients were classified as controls. The local
Medical Ethics Committee (Research and Development
Department, St. Antonius Hospital) approved the study.
Outcome assessment
The primary outcome was postoperative infection within
30 days of surgery. We used the following approach to deter-
mine if a postoperative infection was present: first, all patients
on postoperative antibiotic therapy, aside from perioperative
antibiotic prophylaxis, were identified. Secondly, N.H. and
T.R. independently examined the medical records of these
patients to determine if clinical data (e.g. fever, white cell
count) supported the diagnosis of infection. When N.H. and
T.R. agreed that a postoperative infection was present, it was
classified as a surgical site or non-surgical site infection.
Subsequently, M.S. and T.R. used microbiological data to
identify the microbial aetiology. When N.H., T.R. and M.S.
could not reach an agreement on whether an infection was
present or on the site of infection, P.N. was consulted. For all
patients, in-hospital mortality was noted.
Potential confounders
To be able to control for potential confounding, medical
information was obtained on risk factors for infection that
could potentially confound the association between statin
treatment and outcome. For each patient we evaluated the
presence of the following comorbidities as potential con-
founders: diabetes, chronic obstructive pulmonary disease
(COPD, graded according to the GOLD classification [9]
where all smokers were considered class I unless otherwise
stated), peripheral artery disease, three-vessel coronary artery
disease, renal insufficiency (defined as serum creatinine
>120 μmol/l), heart failure (according to New York Heart
Association functional classification), prior myocardial infarc-
tion, and history of cardiac surgery. In addition, the following
surgery-related parameters were assessed: type of surgery
(coronary artery bypass graft (CABG), valve surgery, aortic
surgery or other), urgent procedure (patients not electively
admitted for operation who require surgery before hospital
discharge), perfusion time, aortic clamp time and whether
rethoracotomy has taken place. Aspirin, antidiabetic agents,
beta-blockers, angiotensin-converting enzyme (ACE) inhibi-
tors, proton pump inhibitors (PPIs) and prednisone were ex-
amined as possible confounding drugs. A patient was consid-
ered exposed to a drug if it was listed in the preoperative
medication profile. Furthermore, we calculated the body mass
index and European System for Cardiac Operative Risk Eval-
uation (EURO) score as proxy for overall health status and
complication risk. During the study period, glucose values
were standardly targeted at 4.5–8 mmol/l during surgery and
ICU admission, and 4.5–10 mmol/l on the surgical ward in all
patients.
Statistical analysis
Data were analysed using International Business Machines
Statistical Package for the Social Science (IBM SPSS) Statis-
tics 19.0 software. Univariate analysis by χ2 tests and Stu-
dent’s t tests was used to test for significant differences in
characteristics between statin users and non-users and patients
with and without postoperative infections. Multivariable
logistic regression analysis was used to estimate the
strength of the association between statin treatment and
the risk of postoperative infection and expressed as odds
ratios (OR) with 95 % confidence intervals (CI). First, we
included all potential confounders and age and gender in a
multivariable model if a variable was imbalanced (P<0.10)
related to either statin use or occurrence of infection.
Second, a final model was obtained after stepwise back-
ward elimination of potential confounders if they did
not alter the OR by more than 10 %. Stratified analyses
were conducted to detect possible differences in effects
related to timing of statin exposure (continued use, commenced
use or discontinued use). For all tests, a P-value of 0.05 was
considered significant.
Results
A total of 370 (71.2 %) patients received statin treatment until
the day of surgery, while 150 (28.8 %) patients did not.
Patients receiving statin treatment were more likely to be
male, and suffering from COPD, diabetes, peripheral artery
disease, and three-vessel coronary artery disease. Further-
more, they experienced more myocardial infarction and iso-
lated CABG surgery and received more frequent other cardio-
vascular drug therapies, such as aspirin, beta-blockers and
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ACE-inhibitors. Compared with non-users, patients on statin
therapy had shorter perfusion times and aortic clamp times.
Baseline characteristics are shown in Table 1.
Overall, 82 (15.8 %) patients suffered from postoperative
infection. Of the patients with an infectious complication,
87 % had a non-surgical site infection. The occurrence of a
surgical site infection was less common and was present in
13 % of patients with postoperative infection. Pneumonia was
the most common infection and accounted for 59 % of all
infectious complications. In 59 (72 %) patients with a
postoperative infection, one or more microorganisms were
detected. Characteristics of patients with and without postop-
erative infection are shown in Table 2.
Patients on preoperative statin therapy suffered less fre-
quently from postoperative infection compared with non-
users (12.2 % versus 24.7 %, respectively; adjusted odds ratio
(AOR): 0.329, 95 % CI: 0.19–0.57; P<0.001; Table 3). Statin
users had fewer non-surgical site infections compared with
non-users (AOR: 0.253, 95 % CI: 0.14–0.45; P<0.001). This
was mainly caused by a reduction in postoperative pneumonia
Table 1 Patient characteristics
according to the use of statins
Dichotomous variables are
shown as number (%) and
continuous variables are
presented as mean ± SD
Variable Statin group
(n=370)
Control group
(n=150)
p-value
Patient characteristics
Sex (male) 260 (70.3) 87 (58.0) 0.007
Age (years) 68.3±10.0 69.5±13.7 0.277
BMI (kg/m2) 27.7±4.5 26.7±4.9 0.037
COPD 206 (55.7) 70 (46.7) 0.062
Diabetes 112 (30.3) 27 (18.0) 0.004
Congestive heart failure 140 (37.8) 75 (50.0) 0.011
Renal failure 56 (15.1) 28 (18.7) 0.322
Peripheral artery disease 79 (21.4) 19 (12.7) 0.018
Three-vessel coronary artery disease 209 (56.5) 30 (20.0) <0.001
EURO score 5.2±3.7 5.7±3.3 0.106
Previous myocardial infarction 180 (48.6) 24 (16.0) <0.001
Previous cardiac surgery 39 (10.5) 23 (15.3) 0.127
Preoperative medication
Beta-blocker 293 (79.2) 91 (60.7) <0.001
ACE-inhibitor 163 (44.1) 47 (31.3) 0.007
Prednisone 43 (11.6) 16 (10.7) 0.756
Proton pump inhibitor 161 (43.5) 60 (40.0) 0.463
Aspirin 150 (40.5) 23 (15.3) <0.001
Postoperative medication
Statin 349 (94.3) 37 (24.7) <0.001
Beta-blocker 301 (81.4) 110 (73.3) 0.056
ACE-inhibitor 168 (45.4) 68 (45.3) 0.968
Prednisone 35 (9.5) 21 (14.0) 0.126
Proton pump inhibitor 272 (73.5) 103 (68.7) 0.291
Type of surgery
CABG 219 (59.2) 25 (16.7) <0.001
Major procedure (other or in addition to CABG) 152 (41.1) 124 (82.7) <0.001
Valve surgery 110 (29.7) 90 (60.0) <0.001
Aortic surgery 22 (5.9) 28 (18.7) <0.001
Other cardiac surgery 9 (2.4) 19 (12.7) <0.001
Perioperative characteristics
Perfusion time (min) 88.6±55.6 126.8±415.5 0.084
Aortic clamp time (min) 60.0±37.9 59.2±55.4 0.836
Off pump 12 (3.2) 3 (2.0) 0.443
Urgent surgery 33 (8.9) 9 (6.0) 0.268
Rethoracotomy 29 (7.8) 20 (13.3) 0.053
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and urinary tract infection (Table 4). A surgical site infection
occurred in 11 (3 %) patients on statin therapy, whereas non-
users did not develop any. Overall, in-hospital mortality was
4.4 %; 3.2 % in patients on preoperative statin therapy and
7.3 % in non-users (P=0.041).
After surgery, statin therapy was initiated in 37 (7.1 %)
patients who did not use statins prior to surgery. Postoperative
initiation of statin therapy was not associated with a reduced
risk of infection (AOR: 0.676, 95% CI: 0.26–1.75; P=0.422).
Discussion
In this cohort of 520 patients undergoing cardiac surgery,
preoperative statin therapy was associated with a 67 %
reduced risk of a postoperative infectious complication.
The reduction in postoperative infection by preoperative
statin use was mainly caused by a reduction in non-
surgical site infections, in particular less pneumonia and
urinary tract infections.
Table 2 Patient characteristics
according to the occurrence of
postoperative infection
Dichotomous variables are
shown as number (%) and
continuous variables are
presented as mean ± SD
Variable Infection group
(n=82)
Control group
(n=438)
p-value
Patient characteristics
Sex (male) 56 (68.3) 291 (66.4) 0.744
Age (years) 70.2±12.0 68.4±11.0 0.189
BMI (kg/m2) 27.8±4.9 27.3±4.6 0.393
COPD 57 (69.5) 219 (50.0) 0.001
Diabetes 21 (25.6) 118 (26.9) 0.803
Congestive heart failure 41 (50.0) 174 (39.7) 0.083
Renal failure 20 (24.4) 64 (14.6) 0.027
Peripheral artery disease 18 (22.0) 80 (18.3) 0.389
Three-vessel coronary artery disease 40 (48.8) 199 (45.4) 0.494
EURO score 6.0±3.5 5.2±3.6 0.074
Previous myocardial infarction 27 (32.9) 177 (40.4) 0.197
Previous cardiac surgery 9 (11.0) 53 (12.1) 0.773
Preoperative medication
Statin 45 (54.9) 325 (74.2) 0.000
Beta-blocker 58 (70.7) 326 (74.4) 0.484
ACE-inhibitor 31 (37.8) 179 (40.9) 0.604
Prednisone 15 (18.3) 44 (10.0) 0.031
Proton pump inhibitor 34 (41.5) 187 (42.7) 0.836
Aspirin 26 (31.7) 147 (33.6) 0.744
Postoperative medication
Statin 45 (54.9) 341 (77.9) 0.000
Beta-blocker 60 (73.2) 351 (80.1) 0.143
ACE-inhibitor 36 (43.9) 200 (45.8) 0.756
Prednisone 13 (15.9) 43 (9.8) 0.109
Proton pump inhibitor 53 (64.6) 322 (73.9) 0.087
Type of surgery
CABG 34 (41.5) 210 (47.9) 0.280
Major procedure (other or in addition to CABG) 47 (57.3) 229 (52.3) 0.402
Valve surgery 32 (39.0) 168 (38.4) 0.909
Aortic surgery 9 (11.0) 41 (9.4) 0.649
Other cardiac surgery 4 (4.9) 24 (5.5) 0.825
Perioperative characteristics
Perfusion time (min) 106.1±72.8 98.4±246.9 0.781
Aortic clamp time (min) 65.6±50.8 58.7±42.1 0.185
Off pump 0 (0.0) 15 (3.4) 0.089
Urgent surgery 8 (9.8) 34 (7.8) 0.543
Rethoracotomy 11 (13.4) 38 (8.7) 0.180
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Recently two meta-analyses studied the relationship
between statins and outcome in patients undergoing
high-risk cardiac procedures (e.g. CABG, valve replace-
ment, percutaneous coronary intervention). Guay et al.
included 29 randomised controlled trials in which statin
therapy was compared with placebo. [10] Statin therapy
reduced the risk of myocardial infarction (risk ratio
(RR): 0.48; 95 % CI 0.38–0.61; P<0.001) and there
was a trend towards lower mortality (RR: 0.26; 95 %
CI 0.06–1.02; P=0.053). Another meta-analysis showed
that preoperative statin therapy was associated with im-
proved outcome after CABG, but not after aortic valve
replacement. [11] However, postoperative infections
were not studied in either studies. Papers investigating
the effect of statins on postoperative infection in cardiac
surgery patients have shown variable results. In a retrospective
cohort study of 1934 patients undergoing CABG and/or valve
surgery, 151 (7.8 %) patients developed an infection. [6]
Preoperative statin use was associated with a risk reduction
of 33 % (P=0.04) for postoperative infection. The odds ratios
for a non-surgical site infection such as pneumonia (OR: 0.67;
95 % CI: 0.43–1.04), urinary tract infection (OR: 0.65; 95 %
CI: 0.31–1.39) or bacteraemia (OR: 0.71; 95%CI: 0.32–1.58)
tended to be less in patients on statins but did not reach
statistical significance. Another retrospective cohort study
from Kayani et al. in 6253 patients who underwent CABG
showed statin use as being associated with a 26% reduction in
the postoperative infection rate (OR: 0.74; 95 % CI: 0.60–
0.90). [12] In contrast, Mohamed et al. studied 7733 patients
undergoing cardiac surgery and in that study statin users had
similar infection rates to nonusers: 8.1 % versus 8.4 %, re-
spectively (AOR: 1.08; 95 % CI: 0.89–1.31). [8] The inci-
dence of any specific infection was similar in both groups,
except for deep sternal/organ space infection (16 (0.6%) statin
users versus 54 (1.1 %) nonusers; P=0.04). Importantly, post-
operative pneumonia was not scored; considering the fact that
pneumonia was diagnosed in 62 % of all infections in the
study by Coleman et al. and 59 % in our study, excluding
pneumonia could have influenced the results in the study by
Mohamed et al.
We noticed a significant difference in infection type be-
tween statin users and nonusers. Patients on statin therapy had
fewer non-surgical site infections, mainly caused by a reduced
incidence of postoperative pneumonia and urinary tract infec-
tion. This finding is consistent with the results of previous
studies. Using the United Kingdom (UK) General Practice
ResearchDatabase, Schlienger et al. performed a retrospective
case–control study in non-surgical patients and showed that
statin therapy was associated with fewer cases of pneumonia,
in particular, fatal pneumonia (OR: 0.47, 95% CI: 0.25–0.88).
[13] Van de Garde et al. showed that in patients with a history
of diabetes only, statin users had a significantly reduced risk of
pneumonia (OR: 0.49, 95 % CI: 0.35–0.69). [14] In contrast,
in our study, surgical site infections occurred more often in
patients on statin therapy than nonusers. This finding has not
been described before. Known risk factors for surgical site
infections, e.g. diabetes, obesity, prolonged operation time,
did not appear to be more common in patients on statins in our
study. Unfortunately, due to the small numbers we were not
able to further investigate these effects with multivariable
analysis. The same applies for potential effects of statins on
mortality. Crude significant reduced in-hospital mortality
could be observed in our study.
If statin therapy is associated with less postoperative non-
surgical site infections, is there a reasonable explanation? It is
known that statins suppress the expression of various cyto-
kines, chemokines and adhesion molecules and modulate
coagulation toward a less prothrombotic state, but is there a
direct effect on bacterial growth? [5] In an experimental study,
mice pretreated with low-dose simvastatin and challenged
with Staphylococcus aureus intratracheally or intravenously
Table 3 Results of multivariate analysis for the effect of statin therapy on
postoperative infection rate
OR (95 % CI) p-value
Unadjusted 0.423 (0.260–0.687) 0.001
Adjusted for sex 0.412 (0.253–0.673) <0.001
Adjusted for sex and age 0.417 (0.255–0.681) <0.001
Adjusted for sex, age and three-vessel
coronary artery disease
0.349 (0.204–0.596) <0.001
Adjusted for sex, age, three-vessel
coronary artery disease and COPD
0.318 (0.184–0.550) <0.001
Adjusted for sex, age, three-vessel
coronary artery disease, COPD and
aortic clamp time more than 90 min
0.329 (0.189–0.572) <0.001
Table 4 Incidence of study endpoints in statin and control group
Statin group
No. (%)
Control group
No. (%)
p-value
All 370 (100) 150 (100)
Postoperative infection 45 (12.2) 37 (24.7) 0.001
Surgical site infection 11 (3.0) 0 (0.0) n.a.*
Mediastinitis 6 (1.6) 0 (0.0)
Wound infection 5 (1.4) 0 (0.0)
Non-surgical site infection 34 (9.2) 37 (24.7) <0.001
Pneumonia 28 (7.6) 20 (13.3)
Urinary tract infection 2 (0.5) 11 (7.3)
Sepsis 3 (0.8) 5 (3.3)
Other 1 (0.3)§ 1 (0.3)¶
In-hospital mortality 12 (3.2) 11 (7.3) 0.041
*n.a.: not available
§ prostatitis
¶ unknown
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had lower lung bacterial burden compared with mice that were
pretreatedwith placebo. [15] Bacterial killing was enhanced in
simvastatin-pretreated mice, while mortality was decreased.
Catron et al. studied mice pretreated with lovastatin and
intraperitoneally infected with Samonella enterica. [16] Intra-
cellular proliferation of Salmonella enterica was inhibited 6-
to 10-fold by lovastatin. In summary, in animals, statins seem
to be bactericidal and decrease bacterial proliferation. How-
ever, well-conducted human studies remain lacking.
During hospitalisation, a patient’s drug treatment is modi-
fied frequently. For example, statin therapy can be initiated
after surgery or discontinued for the remainder of the postop-
erative period. In a recent randomised controlled trial in pa-
tients admittedwith severe sepsis, patients were randomised to
atorvastatin treatment or placebo. [17] Patients in whom statin
treatment was continued showed improved survival, while
new-onset statin treatment did not result in improved out-
come. Our study revealed that statin therapy was initiated in
37 (7 %) patients following surgery. Newly initiated statin
therapy, however, was not associated with a reduced chance of
developing an infection. These results may imply that the
possible protective effect of statin therapy on postoperative
infection is not immediately reached after the start of therapy,
but that it may take weeks before a beneficial effect is apparent.
Compared with other reports, postoperative infection and
mortality rates appeared to be relatively high in our study
population. The most plausible explanation for this could be
the fact that we applied a broad definition for postoperative
infection and that we studied patients who were hospitalised
more than one day before surgery. One could hypothesise
that these patients represent unstable cases and that these
patient have a prolonged risk of nosocomial infections.
Unfortunately, we were not able to test this hypothesis in
depth because of lacking information on outcomes and
antibiotic exposure for the excluded patients. Nevertheless,
the final population in the present study represents the
population that could benefit from interventions such as initi-
ating statins in hospital before surgery if proven beneficial.
Our study has several limitations. First, the results of our
study are limited because the data were derived in a retrospec-
tive manner. Second, compared with similar studies, our study
population is relatively small. And third, we did not have
specific information on the length of statin therapy prior to
surgery, which prevented additional analysis on timing of
statin exposure.
In conclusion, this study describes a protective association
between preoperative statin therapy and postoperative infec-
tious complications in a high-risk cardiac surgical cohort.
Randomised controlled trials are required to further clarify
the role of statin therapy in preventing postoperative infec-
tions in cardiac surgery.
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